BridgeBio Oncology Therapeutics, Inc. (BBOT) stock
BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.94−0.04 (-2.02%)
Close on Nov 17, 2026Market cap $155.54MP/E –Yield –
BridgeBio Oncology Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
BridgeBio Oncology Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$198.96M. For fiscal 2025 it was -$145.82M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$145.82M | – |
| FY2024 | Dec 31, 2024 | -$80.86M | – |
| FY2023 | Dec 31, 2023 | -$41.69K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$60.19M | – |
| Q1 FY2026 | Mar 31, 2026 | -$46.18M | – |
| Q4 FY2025 | Dec 31, 2025 | -$43.41M | – |
| Q3 FY2025 | Sep 30, 2025 | -$49.18M | – |
| Q2 FY2025 | Jun 30, 2025 | -$30.09M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.14M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.88M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.66M | – |
| Q2 FY2024 | Jun 30, 2024 | -$152.34K | – |
| Q1 FY2024 | Mar 31, 2024 | -$66.70K | – |
See a number that looks wrong?